Latest Conference Articles

Combinations May Confer Benefit in MDS Management

Mikkael A. Sekeres, MD, discusses the characteristics of myelodysplastic syndrome and the evolving armamentarium of treatment.

Zonder Addresses Unanswered Questions in Newly Diagnosed Myeloma

Jeffrey A. Zonder, MD, discusses triplet regimens in multiple myeloma and patient eligibility for clinical trials.

Molecular Testing, Immunotherapy To Be Highlighted at 20th Annual Breast Cancer Conference

Advances in subtype-specific treatments, immunotherapy, ongoing issues with younger patients, the optimal use of neoadjuvant and adjuvant regimens, and molecular testing will be discussed at the 20th Annual Lynn Sage Breast Cancer Symposium.

Immunotherapy Combos May Shape the Future of HCC Therapy

The development of novel immunotherapy combinations is among the most significant trends emerging as part of the next wave of discovery in hepatocellular carcinoma, with several promising regimens incorporating checkpoint inhibitors undergoing testing in phase III studies.

Dr. Kudo on Cost-Effectiveness Analysis of Lenvatinib Versus Sorafenib

Masatoshi Kudo, MD, PhD, professor and chairman, Department of Gastroenterology and Hepatology, Kindai University, Osaka, Japan, discusses the results of a cost-effectiveness analysis of lenvatinib versus sorafenib in unresectable hepatocellular carcinoma in Japan.

Dr. Finn on Role of Lenvatinib in HCC Treatment Paradigm

Richard Finn, MD, professor of clinical medicine in the Division of Hematology and Oncology, director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at the University of California, Los Angeles, discusses the role lenvatinib (Lenvima) in the treatment paradigm for advanced hepatocellular carcinoma.

Dr. Lencioni on Assessing Response to HCC Therapy

Riccardo Lencioni, MD, professor in the department of radiology at the University of Pisa School of Medicine in Pisa, Italy, discusses how response to hepatocellular carcinoma (HCC) treatment can be best assessed in patients.

Sangro Says Immunotherapy May Be the Future of HCC Treatment

Bruno Sangro, MD, discussed the current landscape for systemic therapies, new directions with immunotherapy, and the need for greater research into combination therapies for patients with hepatocellular carcinoma.

Regorafenib Sustains OS Benefit in RESORCE Trial Update

Regorafenib maintained a prolonged overall survival benefit as second-line therapy for patients with advanced hepatocellular carcinoma in a 2-year updated analysis of key findings from the pivotal RESORCE trial.

Independent Review Backs Key REFLECT Findings With Lenvatinib in HCC

The positive outcomes that lenvatinib demonstrated as first-line therapy for patients with hepatocellular carcinoma are confirmed in an independent assessment conducted as part of the pivotal, international phase III REFLECT trial.

Dr. Cheng on Tumor Heterogeneity in HCC and Challenges for Clinical Trials

Ann-Lii Cheng, MD, PhD, distinguished professor and director of the cancer center of National Taiwan University, discusses the challenges that tumor heterogeneity in hepatocellular carcinoma (HCC) pose for clinical trials.

Dr. Abou-Alfa on Key Trends in HCC Research

Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, describes what he sees as key areas of research into the treatment of hepatocellular carcinoma as therapy moves beyond existing drugs and into novel approaches.

ILCA President Highlights Progress, Looks to the Future of HCC Treatment

Morris Sherman, MD, PhD, shared his insight on the news and discussions coming out of this year’s meeting, the surge of immunotherapy and targeted therapy research, optimal sequencing approaches, and the challenges that remain in treating patients with hepatocellular carcinoma.

Second-Line Cabozantinib Proves Effective in HBV+ Liver Cancer

Cabozantinib improved survival as second-line therapy for patients with hepatocellular carcinoma who also had a history of hepatitis B virus infection.

Atezolizumab Combo Promising as Frontline HCC Therapy

The combination of atezolizumab and bevacizumab demonstrated strong signals of efficacy with a tolerable safety profile as first-line therapy for patients with unresectable or metastatic hepatocellular carcinoma.

Dr. Villanueva on Liquid Biopsy for HCC

Augusto Villanueva, MD, PhD, assistant professor, Icahn School of Medicine, discusses the potential of liquid biopsy to improve treatment for patients with hepatocellular carcinoma (HCC).

Dr. Llovet on Biomarkers for HCC

Josep M. Llovet, MD, PhD, Icahn School of Medicine, discusses the potential for biomarkers to improve the treatment of hepatocellular carcinoma (HCC).

Novel Agents Prompt Need for New Sequencing Strategies in HCC

The rapid development of novel therapies for patients with unresectable hepatocellular carcinoma has dramatically expanded the options for systemic treatments over the past 2 years, creating the need for new sequencing strategies.

Expert Explores Emerging Role of Personalized Medicine in HCC Treatment

Updates to the European Association for the Study of the Liver clinical guidelines introduce more opportunities for individual patient management of hepatocellular carcinoma.

Frontline Immunotherapy Poses Fresh Dilemma for Sequencing in NSCLC

As the checkpoint inhibitors move into the frontline setting for patients with non–small cell lung cancer, the focus has been placed on the duration of therapy and what to do in the second-line setting following progression.

Optimal Sequence of EGFR TKI Therapy for NSCLC Under Investigation

Recent positive clinical trial data have provided the oncology community with several sequencing strategies for patients with EGFR-mutant non-small cell lung cancer.

Targeted Therapies on Horizon for RET-Rearranged NSCLC

RET is set to join the list of ever-expanding actionable driver mutations for non–small cell lung cancer, as there are now 3 highly effective therapies in development.

Mok Debates First-Line Versus Second-Line TKI Use in Oncogene-Driven NSCLC

The use of frontline versus second-line tyrosine kinase inhibitor use is controversial in many oncogene-driven non-small cell lung cancers.

Dr. Wakelee on Recent Advancements in EGFR-Mutant NSCLC

Heather Wakelee, MD, associate professor of medicine (oncology) at the Stanford University Medical Center, discussed the latest therapeutic developments in EGFR-mutant non-small cell lung cancer.

Dr. Herbst on Intriguing Immunotherapy Combinations in NSCLC

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine and professor of pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; associate director for Translational Research, Yale Cancer Center; Disease Aligned Research Team (DART) Leader, Thoracic Oncology Program, Yale Cancer Center, discusses immunotherapy combinations that have potential in non-small cell lung cancer (NSCLC).

Evolving Lung Cancer Landscape Likely to Involve More Basket Trials

Vassiliki A. Papadimitrakopoulou, MD, shares insight on how the lung cancer paradigm continues to evolve with the identification of targetable driver mutations, the challenges that remain, and the ongoing clinical trial efforts designed to better reach patients and improve their outcomes.

Checkpoint Inhibition Greatest Success in Recent Years for Locally Advanced NSCLC

Checkpoint inhibition following chemoradiation has shown remarkable successes for patients with locally advanced non–small cell lung cancer, after more than 2 decades without major advances.

Immunotherapy Combos Rapidly Evolving for Lung Cancer

The past year has witnessed an explosion in immunotherapy combinations for patients with lung cancer, accompanied by a growing knowledge of biomarkers such as PD-L1 and tumor mutation burden; however, an exact standard of care remains elusive.

Dr. Bunn on Immunotherapy Advances in Small Cell Lung Cancer

Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care

Dr. Reckamp on MET-Targeting Strategies in NSCLC

Karen Reckamp, MD, co-director, Lung Cancer and Thoracic Oncology Program, medical director, Clinical Research Operations, professor, Department of Medical Oncology & Therapeutics Research, thoracic oncologist, discusses current and emerging therapeutic strategies to target MET in non-small cell lung cancer.